Social Media Ideas for Alny

Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

Alnylam (ALNY) Q2 2026 Earnings Call Transcript

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

Amyloidosis Continues To Fight Back

Alnylam plunges as earnings deliver ‘one-two punch’

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM

As AstraZeneca appears to close the book on a combo approach following the phase 3 failure of its Ionis-partnered Wainua, several analysts contend it’s too early to count out Alnyl...

AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial

Denali Therapeutics: Bullish On Avlayah And Their Prospects

Rosen Law Firm Encourages Alarum Technologies Ltd. Investors to Inquire About Securities Class Action Investigation - AL...

NEW YORK, July 20, 2026 /PRNewswire/ --

ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.

AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies

ADARx has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing clinical trials of a range of next-gen small interfering RNA medicines.

Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug

Royalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca...

ALAR Investors Have Opportunity to Lead Alarum Technologies Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Alarum Technologies Ltd. (NASDAQ: ALAR) between...

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing

Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.

ALAR Investors Have Opportunity to Lead Alarum Technologies Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Alarum Technologies Ltd. (NASDAQ: ALAR) between...

AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline

Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innov...

SHANGHAI and HONG KONG, Aug. 23, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedi...

Alkermes plc 2026 Q2 - Results - Earnings Call Presentation

BioMarin to acquire Alesta Therapeutics for up to $490 million

AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on...

Silence Therapeutics: PV Data Could Wake The Stock (Initiating Buy)

<![CDATA[Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for $450 Million ]]>

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so farAnti...

Market Update: NLY, BRO, SANM, SLB, RHHBY, BKR

Astera Labs, Inc. (ALAB) Q2 2026 Earnings Call Transcript